Unlocking R&D Tax Relief in UK Biomedical and Healthcare Technology

Many of the UK’s strongest R&D claims arise from applied biomedical and healthcare technology projects, where teams are improving medically certified technology’s performance, safety, accuracy, and real-world clinical usability. British life sciences and Medtech has a long-standing reputation for translating science into practical outcomes, from diagnostics and medical devices to digital health platforms and advanced therapeutics.  

This blog outlines examples of activities that can potentially qualify for R&D tax purposes and how biomedical and technology-led companies can align to HMRC’s guidance, with examples spanning diagnostics, medical devices, laboratory systems, digital health, and data-driven clinical technologies. 

As with all qualifying R&D projects, a company must seek to align with the R&D guidance and criteria, as outlined within the support CIRD (Corporate Intangibles Research and Development) manuals and Part 13 CTA 2009. Alongside this, the company must be able to demonstrate that a competent professional in the field could not readily determine whether something was possible, or how to achieve it, without structured experimentation, modelling, testing, or analysis. 

Activities which may align include developing a diagnostic assay where sensitivity, specificity, or robustness cannot be achieved using established protocols, particularly when dealing with low-biomass samples, inhibitors, or complex matrices such as blood, saliva, or tissue. Similarly, engineering a medical device to meet safety and performance requirements, whilst reducing size, weight, or power consumption, can require significant iterative prototyping, verification, and validation. 

Further examples include the design and execution of iterative experimental programmes to develop and certify pathogen-specific decontamination cycles capable of reliably eliminating highly resistant organisms, resulting in the development of decontamination system. Alongside qualifying activity includes the development of improved vapour distribution strategies and injection profiles to achieve consistent micro-condensation and surface coverage in small, obstructed or high-absorbency environments, where vapour performance and material interactions were not predictable from baseline systems and required structured trials to improve repeatability and reliability in clinical and laboratory settings. 

Prototyping can qualify where it is undertaken to generate data and resolve uncertainty, not simply to produce a first unit. This can include iterative device builds to test biocompatibility, sterilisation compatibility, sensor drift, failure modes, and long-term reliability. Trials that fail can still qualify, as they evidence uncertainty and technical complexity, provided they contribute to the advancement. 

If you would like to arrange a meeting to discuss what opportunities there are for Medical / Clinical businesses or any R&D services that Streets offer, please see the link below for the team’s Calendly. https://calendly.com/streets-innovation/enquiry-resolution-service